1-12 of 12
Mohammad Luqman
Close
Save search
Follow your search
Access your saved searches in your account
Would you like to receive an alert when new items match your search?
Close Modal
Sort by
Journal Articles

The antileukemia activity of a human anti-CD40 antagonist antibody, HCD122, on human chronic lymphocytic leukemia cells

Mohammad Luqman, Sha Klabunde, Karen Lin, Georgios V. Georgakis, Anu Cherukuri, Jocelyn Holash, Cheryl Goldbeck, Xiaomei Xu, Edward E. Kadel, III, Sang Hoon Lee, Sharon Lea Aukerman, Bahija Jallal, Natasha Aziz, Wen-Kai Weng, William Wierda, Susan O'Brien, Anas Younes
Journal: Blood
Blood (2008) 112 (3): 711–720.
https://doi.org/10.1182/blood-2007-04-084756
Published: 2008
Journal Articles

HCD122, an Antagonist Human Anti-CD40 Monoclonal Antibody, Enhances Efficacy of CHOP in Tumor Xenograft Model of Human Diffuse Large B-Cell Lymphoma.

Mohammad Luqman, PhD, Ssucheng J. Hsu, Ph.D., Matthew Ericson, Sha Klabunde, M.D., Seema Kantak, Ph.D.
Journal: Blood
Blood (2007) 110 (11): 528.
https://doi.org/10.1182/blood.V110.11.528.528
Published: 2007
Journal Articles

Efficacy of an Antagonistic Anti-CD40 Monoclonal Antibody, HCD122 (CHIR-12.12), in Preclinical Models of Human Non-Hodgkin’s Lymphoma and Hodgkin’s Disease.

Li Long, PhD, Montesa Patawaran, B.Sc., Xia Tong, M.Sc., Seema Kantak, Ph.D., Sharon L. Aukerman, Ph.D., Nancy Pryer, Ph.D., Mohammad Luqman, Ph.D.
Journal: Blood
Blood (2006) 108 (11): 230.
https://doi.org/10.1182/blood.V108.11.230.230
Published: 2006
Journal Articles

Antagonist Anti-CD40 Antibody, CHIR-12.12, Induces ADCC, Inhibits Tumor Growth, and Prolongs Survival in a Human Multiple Myeloma Xenograft Model.

Li Long, PhD, Xia Tong, M.Sc, Montesa Patawaran, B.Sc, Sharon L. Aukerman, PhD, Bahija Jallal, PhD, Mohammad Luqman, PhD
Journal: Blood
Blood (2005) 106 (11): 3470.
https://doi.org/10.1182/blood.V106.11.3470.3470
Published: 2005
Journal Articles

A Non-Internalizing Anti-CD40 Antibody, CHIR-12.12, Blocks CD40L-Induced Cytokine Production and Mediates Greater ADCC Than Rituximab in Primary CLL Cells.

Xia Tong, MSc, Sharon Lea Aukerman, PhD, Karen Lin, BS, Natasha Aziz, PhD, Cheryl Goldbeck, BS, Georgios V. Georgakis, MD, Anas Younes, MD, Wen-Kai Weng, MD, PhD, Susan O’Brien, MD, William Wierda, MD, PhD, Bahija Jallal, PhD, Mohammad Luqman, PhD
Journal: Blood
Blood (2005) 106 (11): 2964.
https://doi.org/10.1182/blood.V106.11.2964.2964
Published: 2005
Journal Articles

Human Antagonistic Anti-CD40 Antibody, CHIR-12.12, Inhibits CD40-Mediated Survival of Chronic Lymphocytic Leukemia B Cells Leading to Cellular Apoptosis.

Anu Cherukuri, PhD, Edward Kadel, BS, Sang H. Lee, PhD, Cheryl Goldbeck, BS, Carla Heise, PhD, Mohammad Luqman, PhD, Sharon L. Aukerman, PhD, Natasha Aziz, PhD, Susan O’Brien, MD, William G. Wierda, MD, PhD, Bahija Jallal, PhD
Journal: Blood
Blood (2005) 106 (11): 2965.
https://doi.org/10.1182/blood.V106.11.2965.2965
Published: 2005
Journal Articles

CHIR-12.12, an Antagonist Anti-CD40 Antibody, Exhibits Greater ADCC Than Rituximab Against a Variety of Malignant B Cells: Evaluation of FcγRIIIa Polymorphism and ADCC Response.

Mohammad Luqman, PhD, Xia Tong, MSc, Xiaohong Niu, BS, Pablo Garcia, PhD, Michel Faure, PhD, Asha Yabannavar, PhD, Bahija Jallal, PhD
Journal: Blood
Blood (2005) 106 (11): 1472.
https://doi.org/10.1182/blood.V106.11.1472.1472
Published: 2005
Journal Articles

A Fully Human Anti-CD40 Antagonistic Antibody, CHIR-12.12, Inhibit the Proliferation of Human B Cell Non-Hodgkin’s Lymphoma.

Wen-Kai Weng, MD, PhD, Xia Tong, Mohammad Luqman, PhD, Ronald Levy, MD
Journal: Blood
Blood (2004) 104 (11): 3279.
https://doi.org/10.1182/blood.V104.11.3279.3279
Published: 2004
Journal Articles

Antagonist Anti-CD40 Monoclonal Antibody, CHIR-12.12, Inhibits Growth of a Rituximab-Resistant NHL Xenograft Model and Achieves Synergistic Activity When Combined with Ineffective Rituximab.

Li Long, Ph.D., Xia Tong, M.Sc., Montesa Patawaran, B.Sc., Lea Aukerman, Ph.D., Julie Klinger, Ph.D., Bahija Jallal, Ph.D., Mohammad Luqman, Ph.D.
Journal: Blood
Blood (2004) 104 (11): 3281.
https://doi.org/10.1182/blood.V104.11.3281.3281
Published: 2004
Journal Articles

Safety Evaluation of an Fully Human Antagonist Anti-CD40 Antibody, CHIR-12.12, in a Dose Range-Finding Study in Cynomolgus Monkeys.

Ursula B. Jeffry, Kay Huh, Xia Tong, Julie Klinger, Werner Frings, Antje Fuchs, Nancy Turner, Mohammad Luqman
Journal: Blood
Blood (2004) 104 (11): 3282.
https://doi.org/10.1182/blood.V104.11.3282.3282
Published: 2004
Journal Articles

Immunological Profile and Safety Evaluation in a 23-Week Single Dose Study in Cynomolgus Monkey with CHIR-12.12, a Fully Human Antagonist Anti-CD40 Antibody.

Ursula B. Jeffry, Mohammad Luqman, Kay Huh, Julie Klinger, Werner Frings, Nancy Turner
Journal: Blood
Blood (2004) 104 (11): 4638.
https://doi.org/10.1182/blood.V104.11.4638.4638
Published: 2004
Journal Articles

Antagonist Anti-CD40 Antibody CHIR-12.12 Causes Tumor Regression and Prolongs Survival in Multiple Myeloma Xenograft Models.

Li Long, Ph.D., Xia Tong, M.Sc., Montesa Patawaran, B.Sc., Lea Aukerman, Ph.D., Bahija Jallal, Ph.D., Mohammad Luqman, Ph.D.
Journal: Blood
Blood (2004) 104 (11): 4888.
https://doi.org/10.1182/blood.V104.11.4888.4888
Published: 2004